Finch Therapeutics Total Debt vs. Revenue

FNCHDelisted Stock  USD 8.51  0.19  2.18%   
Based on Finch Therapeutics' profitability indicators, Finch Therapeutics Group may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Finch Therapeutics' ability to earn profits and add value for shareholders.
For Finch Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Finch Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Finch Therapeutics Group utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Finch Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Finch Therapeutics Group over time as well as its relative position and ranking within its peers.
  
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Please note, there is a significant difference between Finch Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Finch Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Finch Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Finch Therapeutics Revenue vs. Total Debt Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Finch Therapeutics's current stock value. Our valuation model uses many indicators to compare Finch Therapeutics value to that of its competitors to determine the firm's financial worth.
Finch Therapeutics Group is rated # 5 in total debt category among its peers. It is rated below average in revenue category among its peers . The ratio of Total Debt to Revenue for Finch Therapeutics Group is about  281.55 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Finch Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Finch Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Finch Total Debt vs. Competition

Finch Therapeutics Group is rated # 5 in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 297.05 Million. Finch Therapeutics retains roughly 30.13 Million in total debt claiming about 10% of equities under Health Care industry.
Total debt  Capitalization  Revenue  Workforce  Valuation

Finch Revenue vs. Total Debt

Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Finch Therapeutics

Total Debt

 = 

Bonds

+

Notes

 = 
30.13 M
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Finch Therapeutics

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
107 K
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Finch Revenue vs Competition

Finch Therapeutics Group is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 61.7 Million. Finch Therapeutics adds roughly 107,000 in revenue claiming only tiny portion of equities under Health Care industry.

Finch Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Finch Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Finch Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Finch Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Finch Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts. Finch Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 189 people.

Finch Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Finch Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Finch Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Finch Therapeutics' important profitability drivers and their relationship over time.

Use Finch Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Finch Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Finch Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Finch Therapeutics Pair Trading

Finch Therapeutics Group Pair Trading Analysis

The ability to find closely correlated positions to Finch Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Finch Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Finch Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Finch Therapeutics Group to buy it.
The correlation of Finch Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Finch Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Finch Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Finch Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Finch Therapeutics position

In addition to having Finch Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Disruptive Technologies Thematic Idea Now

Disruptive Technologies
Disruptive Technologies Theme
New or established technology companies and funds across multiple sectors that are involved in development or marketing of products or services that experience disruptive trends and that are at the forefront of discussions on Wall Street. The Disruptive Technologies theme has 64 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Disruptive Technologies Theme or any other thematic opportunities.
View All  Next Launch
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Other Consideration for investing in Finch Pink Sheet

If you are still planning to invest in Finch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Finch Therapeutics' history and understand the potential risks before investing.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Global Correlations
Find global opportunities by holding instruments from different markets
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges